Evidence map›Paper›PMID 26701233›Full record

Observational studyThe Korean journal of internal medicine2016

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.

Jang Hoon Lee, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim and 2 more

Open access · goldAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Korean journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jang Hoon LeeDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Myung Hwan BaeDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Dong Heon YangDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Hun Sik ParkDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Yongkeun ChoDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Won Kee LeeDepartment of Preventive Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Myung Ho JeongDepartment of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Young Jo KimDepartment of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Myeong Chan ChoDepartment of Internal Medicine, Chungbuk National University School of Medicine, Cheongju, Korea.
Chong Jin KimDepartment of Internal Medicine, Kyung Hee University East-West Neo Medical Center, Seoul, Korea.
Shung Chull ChaeDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Korea Acute Myocardial Infarction Registry Investigators
Kyungpook National University · KRChonnam National University Hospital · KRChungbuk National University · KRKyung Hee University East-West Neo Medical Center · KRYeungnam University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsAngiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI).

methodsBetween November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the Korean AMI Registry. The primary endpoints were 12-month major adverse cardiac events (MACEs) including death and recurrent AMI.

resultsSeventy percent of the patients were Killip class 1 and had a LV ejection fraction ≥ 40%. The prescription rate of ARBs was 12.2%. For each patient, a propensity score, indicating the likelihood of using ARBs during hospitalization or at discharge, was calculated using a non-parsimonious multivariable logistic regression model, and was used to match the patients 1:4, yielding 715 ARB users versus 2,860 ACEI users. The effect of ARBs on in-hospital mortality and 12-month MACE occurrence was assessed using matched logistic and Cox regression models. Compared with ACEIs, ARBs significantly reduced in-hospital mortality(1.3% vs. 3.3%; hazard ratio [HR], 0.379; 95% confidence interval [CI], 0.190 to0.756; p = 0.006) and 12-month MACE occurrence (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; p = 0.028). However, the benefit of ARBs on 12-month mortality compared with ACEIs was marginal (4.3% vs. 6.2%; HR, 0.684; 95% CI, 0.467 to 1.002; p = 0.051).

conclusionsOur results suggest that ARBs are not inferior to, and may actually be better than ACEIs in Korean patients with AMI.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersChi-Square DistributionHospital MortalityHumansKaplan-Meier EstimateLogistic ModelsMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsProspective StudiesRecurrenceRegistriesRepublic of KoreaRisk FactorsSecondary PreventionAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin-converting enzyme inhibitorsAngiotensin II type 1 receptor blockersMortalityMyocardial infarctionSecondary prevention

Identifiers

PMID26701233
PMCPMC4773713
OpenAlexW2264365055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.